Combination of temsirolimus and adriamycin exhibits an enhanced antitumor effect in hepatocellular carcinoma

Clinics and Research in Hepatology and Gastroenterology

Volumn 41, Issue 2, 2017, Pages 197-203

  Kang, Hong Gang ^a   Wang, Bao Zhong ^a   Zhang, Jing ^a   Liu, Mei Rong ^a   Li, Ying Xue ^a  

^a LIAOCHENG PEOPLE'S HOSPITAL   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CASPASE 9; DOXORUBICIN; MAMMALIAN TARGET OF RAPAMYCIN; PARP PROTEIN; PROTEIN; PROTEIN BAX; PROTEIN BCL 2; TEMSIROLIMUS; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; ANTINEOPLASTIC ANTIBIOTIC; MTOR PROTEIN, HUMAN; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; RAPAMYCIN; TARGET OF RAPAMYCIN KINASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER INHIBITION; CELL GROWTH; CELL PROLIFERATION; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; FEMALE; FLOW CYTOMETRY; IN VITRO STUDY; IN VIVO STUDY; LIVER CELL CARCINOMA; MOUSE; MTT ASSAY; NONHUMAN; PROTEIN EXPRESSION; TUMOR GROWTH; UPREGULATION; WESTERN BLOTTING; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; HUMAN; LIVER TUMOR; NUDE MOUSE; PATHOLOGY; TUMOR CELL LINE;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASE 9; CELL LINE, TUMOR; CELL PROLIFERATION; DOXORUBICIN; HUMANS; LIVER NEOPLASMS; MICE; MICE, NUDE; POLY(ADP-RIBOSE) POLYMERASES; SIROLIMUS; TOR SERINE-THREONINE KINASES;

EID: 85006789341     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/j.clinre.2016.09.005     Document Type: Article

References (20)

1. [1] Torre, L.A., Bray, F., Siegel, R.L., Ferlay, J., Lortet-Tieulent, J., Jemal, A., Global cancer statistics, 2012. CA Cancer J Clin 65:2 (2015), 87–108.
2. [2] American Cancer Society, Cancer facts and figs. 2005 http://wwwcancerorg/docroot/home/indexasp [accessed 21.10.15].
3. [3] Johnson, P.J., Non-surgical treatment of hepatocellular carcinoma. HPB (Oxford) 7:1 (2005), 50–55.
4. [4] Gao, J., Feng, X., Inagaki, Y., Song, P., Kokudo, N., Hasegawa, K., et al. Des-gamma-carboxy prothrombin and c-Met were concurrently and extensively expressed in hepatocellular carcinoma and associated with tumor recurrence. Biosci Trends 6:4 (2012), 153–159.
5. [5] Cao, H., Phan, H., Yang, L.X., Improved chemotherapy for hepatocellular carcinoma. Anticancer Res 32:4 (2012), 1379–1386.
6. [6] Chen, B.W., Chen, W., Liang, H., Liu, H., Liang, C., Zhi, X., et al. Inhibition of mTORC2 induces cell-cycle arrest and enhances the cytotoxicity of doxorubicin by suppressing MDR1 expression in HCC cells. Mol Cancer Ther 14:8 (2015), 1805–1815.
7. [7] Finn, R.S., Current and future treatment strategies for patients with advanced hepatocellular carcinoma: role of mTOR inhibition. Liver Cancer 1:3–4 (2012), 247–256.
8. [8] Ashworth, R.E., Wu, J., Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol 6:11 (2014), 776–782.
9. [9] Yeo, W., Chan, S.L., Mo, F.K., Chu, C.M., Hui, J.W., Tong, J.H., et al. Phase I/II study of temsirolimus for patients with unresectable Hepatocellular Carcinoma (HCC) – a correlative study to explore potential biomarkers for response. BMC Cancer, 15, 2015, 395.
10. [10] Hui, I.C., Tung, E.K., Sze, K.M., Ching, Y.P., Ng, I.O., Rapamycin and CCI-779 inhibit the mammalian target of rapamycin signalling in hepatocellular carcinoma. Liver Int 30:1 (2010), 65–75.
11. [11] Raje, N., Kumar, S., Hideshima, T., Ishitsuka, K., Chauhan, D., Mitsiades, C., et al. Combination of the mTOR inhibitor rapamycin and CC-5013 has synergistic activity in multiple myeloma. Blood 104:13 (2004), 4188–4193.
12. [12] Matsuzaki, T., Yashiro, M., Kaizaki, R., Yasuda, K., Doi, Y., Sawada, T., et al. Synergistic antiproliferative effect of mTOR inhibitors in combination with 5-fluorouracil in scirrhous gastric cancer. Cancer Sci 100:12 (2009), 2402–2410.
13. [13] Pencreach, E., Guerin, E., Nicolet, C., Lelong-Rebel, I., Voegeli, A.C., Oudet, P., et al. Marked activity of irinotecan and rapamycin combination toward colon cancer cells in vivo and in vitro is mediated through cooperative modulation of the mammalian target of rapamycin/hypoxia-inducible factor-1alpha axis. Clin Cancer Res 15:4 (2009), 1297–1307.
14. [14] Lu, X., Wei, H., Zhang, X., Zheng, W., Chang, C., Gu, J., Rapamycin synergizes with low-dose oxaliplatin in the HCT116 colon cancer cell line by inducing enhanced apoptosis. Oncol Lett 2:4 (2011), 643–647.
15. [15] Acevedo-Gadea, C., Santin, A.D., Higgins, S.A., Urva, S., Ratner, E., Silasi, D.A., et al. Phase I clinical trial of the mammalian target of rapamycin inhibitor everolimus in combination with oral topotecan for recurrent and advanced endometrial cancer. Int J Gynecol Cancer 24:3 (2014), 528–533.
16. [16] Piguet, A.C., Semela, D., Keogh, A., Wilkens, L., Stroka, D., Stoupis, C., et al. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma. J Hepatol 49:1 (2008), 78–87.
17. [17] Lai, C.L., Wu, P.C., Chan, G.C., Lok, A.S., Lin, H.J., Doxorubicin versus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62:3 (1988), 479–483.
18. [18] Burroughs, A., Hochhauser, D., Meyer, T., Systemic treatment and liver transplantation for hepatocellular carcinoma: two ends of the therapeutic spectrum. Lancet Oncol 5:7 (2004), 409–418.
19. [19] Varga, Z.V., Ferdinandy, P., Liaudet, L., Pacher, P., Drug-induced mitochondrial dysfunction and cardiotoxicity. Am J Physiol Heart Circ Physiol 309:9 (2015), H1453–H1467.
20. [20] Degli Esposti, M., Dive, C., Mitochondrial membrane permeabilisation by Bax/Bak. Biochem Biophys Res Commun 304:3 (2003), 455–461.